FDA Fast-Tracks New Cancer Drug for Skin Cancer While Cannabis Science Offers Topical Treatment for Basal Cell Carcinoma with No Apparent Side Effects
Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is very pleased to inform that news of recent FDA Cancer Drug Approval puts Cannabis Science in a very good position moving forward with its current Cancer solutions.
Erivedge was given a fast six-month review because there are no approved treatments for advanced basal cell carcinoma. See FDA Announcement here .
“For the FDA to approve a drug with serious side effects within six months, suggests that the Cannabis Science should receive similar consideration when we submit our application for the treatment of basal cell carcinoma,” said Dr. Melamede, CEO, Cannabis Science. Click here for further information on side effects associated with Erivedge .
Cannabis Science is currently assisting numerous cancer patients suffering from a variety of cancers, who are self-medicating with cannabis extracts. Cannabis Science extracts can be legally used in humans in states allowing medical marijuana. This situation puts Cannabis Science in the unique position of knowing the effectiveness of its formulations before applying to the FDA. The success of Cannabis Science approach is dramatically demonstrated with the photo documentation available on our website www.cannabisscience.com under breaking news. Similar positive results from treating various cancer types have been observed following systemic treatments when more than a topical treatment is required.
“Whereas treatment with Erivedge is estimated to cost $7,000 per month for a total treatment plan of approximately $75,000, the Cannabis Science treatment is estimated to cost at least ten fold less,” added Dr. Melamede. “Because of the FDA focus on protecting the public from the possible harm that is so often associated with conventional pharmaceuticals, the reality of what is happening in medical marijuana states needs be incorporated into the federal approval process. Americans suffering from various forms of cancer, including skin cancer, need the FDA to place patients first when considering our up coming application.”
A comparison between Erivedge and Cannabis Science treatments is informative. According to the FDA: “The most common side effects observed in patients treated with Erivedge were muscle spasms, hair loss, weight loss, nausea, diarrhea, fatigue, distorted sense of taste, decreased appetite, constipation, vomiting, and loss of taste function in the tongue.” Cannabis-based botanicals actually can be used to treat most of these side effects.
Dr. Melamede adds, “How ironic it is that the medicine of the past will become the medicine of the future as safe and cost effective cannabis-based botanicals displace conventional pharmaceuticals for the benefit of mankind.”
You can view the above images as well as all Cannabis Science’ success on the Cannabis Science website www.cannabisscience.com , click “Breaking News” and you will find the associated news releases and images from of each patient. You can view each patient’s documentation and images by clicking: “View Images of 1st Self-Medicated Patient & The Apparent Success”, “View Images of 2nd Self-Medicated Patient & The Apparent Success”, and “View Images of 3rd Self-Medicated Patient & His Apparent Success.”
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President
& CEO
info@cannabisscience.com
www.cannabisscience.com
or
Robert
Kane, 1-561-234-6929
Investor Relations Management
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aksia Welcomes Sebastiaan van den Berg, Christopher Schelling, and Benjamin Parks15.5.2025 16:00:00 CEST | Press release
Aksia is pleased to announce the addition of three distinguished professionals to our team: Sebastiaan van den Berg, Christopher Schelling, and Benjamin Parks. Their extensive experience and expertise will further strengthen Aksia's capabilities and commitment to delivering exceptional service to our clients. Sebastiaan van den Berg joins Aksia as a Partner on the Private Equity team. Sebastiaan will work closely with Aksia’s Pan-Alts and Private Equity teams to support the Firm’s EMEA clients’ Private Equity programs. With over 25 years of experience in global private equity, Sebastiaan brings a wealth of knowledge in portfolio management, investment underwriting, deal sourcing, and the private equity ecosystem. Most recently, Sebastiaan served as Partner, Co-Head GP Equity Solutions at Astorg. Christopher Schelling joins Aksia as a Managing Director on the Pan-Alts team. Chris will be working with Aksia’s data, risk and asset class teams on research projects that benefit Aksia’s clie
Boomi Acquires Thru, Inc., Strengthening Secure Managed File Transfer (MFT) and Advancing Context-Aware Integration15.5.2025 15:00:00 CEST | Press release
Acquisition enhances Boomi’s MFT capabilities, unifying API, application, and file-based data movement within a single platform Boomi™, the leader in AI-driven automation, today announced a definitive agreement to acquire Thru, Inc., a provider of enterprise-grade Managed File Transfer solutions and trusted Boomi partner. The acquisition marks a strategic expansion of Boomi’s file-based integration capabilities, all within a single, cloud-native platform that seamlessly manages data movement across APIs, applications, and files. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515314260/en/ Boomi Acquires Thru, Inc., Strengthening Secure Managed File Transfer (MFT) and Advancing Context-Aware Integration “As organizations increasingly manage a hybrid mix of API-based and file-based integrations, Thru, Inc.’s proven MFT technology ensures secure, scalable, and compliant file exchange across distributed business ecosystems,”
New York Mobile Becomes First U.S. MVNO to Launch on Telness Tech’s Seamless OS15.5.2025 15:00:00 CEST | Press release
New York Mobile is the first U.S. mobile virtual network operator (MVNO) to launch using Telness Tech’s newly launched Seamless OS platform. This deployment enables NY Mobile to deliver a next-generation wireless service, on T-Mobile’s largest and fastest 5G network. NY Mobile will be able to offer unprecedented features and flexibility for its customers including a vanity phone number marketplace and create-your-own-plan options. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515669016/en/ from the left; Jonas Cedenwing (Founder & CTO Telness Tech) Giovanni Perone, Co-Founder & CEO at New York Mobile. Location; One World Trade Center (NY Mobile HQ). Photo taken by Sebastian Stecki. Customers can search and claim personalized phone numbers (including exclusive, previously exhausted area codes, creative number patterns, and words) through New York Mobile’s one-of-a-kind vanity number search engine and marketplace. This mak
Advanced Technologies Enable Reuse of 18.1 Billion Cubic Meters of Water15.5.2025 14:00:00 CEST | Press release
New report shows how utilities and businesses around the world are reusing water, preventing water loss, and creating more water-secure communities Utilities and businesses around the world have reused 18.1 billion cubic meters of water since 2019, enabled by solutions from global water technology leader Xylem (NYSE: XYL), the Company revealed in its most recent Sustainability Report. That volume is enough to meet the annual water needs of more than 350 million people, based on global use estimates.1 Reuse is just one part of a broader effort to increase global water security – alongside the implementation of advanced treatment and digital technologies. Water managers are using the innovations to protect water sources, remove contaminants, reduce emissions, and make water infrastructure more resilient. “Our customers are tackling the world’s toughest water challenges,” said Matthew Pine, Xylem President and Chief Executive Officer. “Their results show the impact of scaling proven techn
Rubicon Carbon Enters into Agreement with Microsoft for Nature-based Carbon Removal Credits15.5.2025 14:00:00 CEST | Press release
This initiative marks one of the largest-ever commitments by a single corporate buyer in the voluntary carbon market to date. Rubicon Carbon, a leading carbon credit management firm, today entered into a framework agreement with Microsoft to facilitate the purchase of 18 million tonnes of high-quality carbon removal credits – one of the largest single-buyer commitments of its kind in the world. Each carbon removal transaction under this deal will be structured as 15- to 20-year offtakes, supporting a pipeline of individual Afforestation, Reforestation, and Revegetation (ARR) projects worldwide. A defining feature of this framework agreement is the scale of Microsoft’s work in this space. By anchoring long-term offtake agreements, this deal demonstrates the growing role of corporate buyers in unlocking private investment for high-integrity carbon projects that might otherwise lack funding. “Addressing climate change requires more than good intentions—it requires capital deployment at sc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom